全球DNA疫苗市場及技術動向

全球DNA疫苗市場及技術動向 是由出版商BCC Research在2009年09月所出版的。 這份英文市場調查報告書包含213 pages 價格從美金4850起跳。

簡介

本報告書內容包括：全球DNA疫苗產業綜合分析、2014年之前的全球市場銷售預測、受矚目的產品及技術動向、疾病別、消費者別疫苗市場定量評價、未來的成長機會及主要企業介紹等。內容綱要摘記如下：

第1章 介紹

第2章 摘要

第3章 概要

• 介紹
• 本書中介紹的DNA疫苗技術
• DNA疫苗市場的促進成長因素
• DNA疫苗技術的生命週期
• DNA疫苗技術商業化
• DNA疫苗產業結構

第4章 DNA疫苗技術

• 歷史
• 人體免疫系統
• 疫苗
• DNA疫苗

第5章 DNA疫苗的應用

• 研究工具
• 臨床

第6章 DNA疫苗產業

• 疫苗產業結構轉換
• 產業結構
• DNA疫苗競爭企業
• DNA疫苗價值鏈
• DNA疫苗競爭企業的策略定位
• 產業的收購及策略合作

第7章 DNA疫苗市場

• 成長動力

第8章 專利動向

• 介紹
• 企業別、技術別專利
• 抗原及相關PDNA
• 地區別DNA疫苗專利
• 價值鏈中的主要產業專利
• 官司動向
• DNA疫苗製造商的智慧財產權

第9章 企業介紹

目錄

Abstract

• Presents a comprehensive analysis of the emerging global DNA vaccine industry
• Forecasts sales in the global market for DNA vaccines through 2014
• Highlights products and technologies that are commercially important in the 2009 to 2014 time period
• Quantifies the DNA vaccines market potential by disease, end use market and technology
• Identifies emerging growth opportunities in DNA vaccine delivery technologies, adjuvants and synthetic genes
• Includes company profiles along with patents by technology and patents by company.

SCOPE OF REPORT

The study scope includes DNA vaccine products that are commercial or likely to be commercialized within the next 5 years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2009 through 2014 is estimated.

The role that DNA vaccines play in the overall vaccines industry is examined, as well as how the vaccine industry structure and dynamics are changing.

We examine DNA synthesis, biotechnology, and pharmaceuticals firms; strategic industry alliances; and the role of gene delivery and synthesis technologies. The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies, and biodefense, are analyzed and the main companies in these fields are highlighted.

METHODOLOGY

Both primary and secondary research methodologies were used to prepare this report. BCC Research surveyed key users and producers in each of the end-user market segments and technology fields that will be commercially important during the next 5 years. Interviews with industry thought leaders were conducted, and an extensive review of secondary sources was done, as well as secondary market research was performed.

A vaccine value-chain method is used to study competitor, technology, and market positioning.

Based on our analysis, we project the future applications of DNA vaccines by market segment and technology type, and forecast sales revenues for 2009 through 2014.

INFORMATION SOURCES

BCC surveyed biotechnology, pharmaceutical, and gene synthesis companies to obtain data for this study. Included were life-science research tools, drug, biotechnology, DNA synthesis firms, as well as leading life-science research institutions. We also spoke with industry thought leaders. In addition, we compiled data from secondary sources, including industry, trade, and government.

ANALYST CREDENTIALS

The author, John Bergin, has written previous BCC biotechnology reports entitled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Markets; Biologic Imaging Reagents: Future Technologies and Markets and Synthetic Biology. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.

Table of Contents

DNA Vaccines: Technologies and Global Markets

Chapter- 1: INTRODUCTION -- Complimentary

• STUDY GOALS AND OBJECTIVES
• REASONS FOR DOING THE STUDY
• INTENDED AUDIENCE
• SCOPE OF REPORT
• METHODOLOGY
• INFORMATION SOURCES
• RELATED BCC REPORTS
• ANALYST CREDENTIALS
• BCC ONLINE SERVICES
• DISCLAIMER

Chapter-2: SUMMARY

• SUMMARY
• SUMMARY TABLE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
• SUMMARY FIGURE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
• SUMMARY (CONTINUED)

Chapter-3: OVERVIEW

• INTRODUCTION
  • TABLE 1 CLINICAL STATUS OF DNA VACCINES, AS OF JULY 2009 (NUMBER)
• DNA VACCINE TECHNOLOGIES COVERED IN THIS REPORT
  • TABLE 2 SCOPE OF THIS REPORT
• GLOBAL MARKET FOR DNA VACCINES
  • TABLE 3 GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
  • TABLE 4 GLOBAL VALUE OF HUMAN DNA VACCINE MARKET BY INDICATION, THROUGH 2014 ($ MILLIONS)
• FORCES DRIVING DNA VACCINE MARKET GROWTH
  • TABLE 5 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
• LIFE CYCLE STATUS OF DNA VACCINE TECHNOLOGIES
  • TABLE 6 LIFE CYCLE STAGE OF VACCINE TYPES
• COMMERCIAL STATUS OF DNA VACCINE TECHNOLOGIES
  • TABLE 7 COMMERCIAL STATUS OF DNA VACCINES
• DNA VACCINE INDUSTRY
  • TABLE 8 DNA VACCINE INDUSTRY STRUCTURE

Chapter-4: DNA VACCINE TECHNOLOGIES

• HISTORY
  • TABLE 9 DNA VACCINE HISTORY
• THE HUMAN IMMUNE SYSTEM
  • TABLE 10 COMPONENTS OF THE IMMUNE SYSTEM
• THE HUMAN IMMUNE SYSTEM (CONTINUED)
• VACCINES
• VACCINE EVOLUTION
  • FIGURE 1 EVOLUTION OF VACCINE TECHNOLOGIES
• VACCINE TYPES
  • TABLE 11 VACCINE TYPES
• Technology Life-Cycle Stage of Vaccine Types
  • TABLE 12 TECHNOLOGY LIFE-CYCLE STAGE OF VACCINE TYPES
• DNA VACCINES
• INTRODUCTION
  • FIGURE 2 MECHANISM OF ACTION OF A DNA VACCINE
• CHANGING VACCINE PARADIGM
  • TABLE 13 CHANGING VACCINE PARADIGM
  • TABLE 14 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES
• Changing Vaccine Paradigm (Continued)
  • FIGURE 3 SAFETY AND EFFICACY PROFILE OF DNA VERSUS VIRAL-VECTOR VACCINES
• FUNCTION AND SCOPE OF DNA VACCINES
  • FIGURE 4 DNA VACCINE FUNCTION AND MARKET SCOPE
  • TABLE 15 EMERGING COMPETITIVE LANDSCAPE FOR DNA VACCINES
• CANCER DNA VACCINES
  • TABLE 16 CANCER VACCINE TYPES
• DNA VACCINE TECHNOLOGY VALUE CHAIN
  • FIGURE 5 DNA VACCINE TECHNOLOGY VALUE CHAIN
  • TABLE 17 TECHNOLOGY DRIVERS FOR DNA VACCINE VALUE CHAIN
• ANTIGEN DISCOVERY
• PLASMID DESIGN
  • TABLE 18 PLASMID DESIGN OBJECTIVES
  • TABLE 19 WAYS TO OPTIMIZE MAMMALIAN GENE EXPRESSION IN PLASMID DNA
• Plasmid Design (Continued)
• PLASMID MANUFACTURE
  • FIGURE 6 CONVENTIONAL AND PLASMID DNA VACCINE PRODUCTION PROCESS
  • TABLE 20 DNA PLASMID QUALITY COMPARSION
• DELIVERY TECHNOLOGIES
  • TABLE 21 COMPARISON OF DNA DELIVERY TECHNOLOGIES
• Uncomplexed pDNA
• Electroporation
  • FIGURE 7 EP PROCESS SCHEMATIC
• Liposomes
• Gold Particles
• Nanoparticles
• Bacterial Ghosts
• Bacteriophages
• Viruses
  • TABLE 22 IN VIVO VIRAL VECTOR TECHNOLOGIES COMPARED
• Viruses (Continued)
• TARGETING TECHNOLOGIES
  • FIGURE 8 STRATEGIES FOR TARGETING DENDRITIC CELLS
• ADJUVANT TECHNOLOGIES
  • TABLE 23 DNA VACCINE ADJUVANT TECHNOLOGIES
• DNA VACCINE TECHNOLOGY NEEDS
  • TABLE 24 TECHNOLOGY NEEDS FOR DNA VACCINES
• DNA Vaccine Technology ...... (Continued)

Chapter-5: DNA VACCINE APPLICATIONS

• RESEARCH TOOLS APPLICATIONS
• CLINICAL APPLICATIONS
• OVERVIEW TO DNA VACCINE CLINICAL TRIALS PROCESS
  • TABLE 25 DNA VACCINE DEVELOPMENT FLOWSHEET
  • TABLE 26 DNA VACCINE PRECLINICAL DEVELOPMENT STEPS
  • FIGURE 9 FUTURE VACCINE CLINICAL TRIALS OVERVIEW
• Overview to DNA ...... (Continued)
• DNA VACCINE CLINICAL TRIALS SUMMARY
  • TABLE 27 DNA VACCINES CLINICAL TRIALS SUMMARY BY DISEASE TYPE, AS OF JULY 2009
  • TABLE 28 DNA VACCINES CLINICAL TRIALS SUMMARY BY DELIVERY TECHNOLOGY, AS OF JULY 2009
  • TABLE 29 DNA VACCINES CLINICAL TRIALS SUMMARY BY VACCINE TYPE, AS OF JULY 2009
  • TABLE 30 DNA VACCINES CLINICAL TRIALS SUMMARY BY VACCINE TYPE AND INDICATION, AS OF JULY 2009
• CANCER DNA VACCINE CLINICAL TRIALS
  • TABLE 31 CANCER DNA VACCINES CLINICAL TRIALS, AS OF 2009
  • TABLE 31 (CONTINUED)
  • TABLE 31 (CONTINUED)
• Melanoma
• Melanoma (Continued)
• Prostate Cancer
• Breast Cancer
• Multiple Cancers
• INFECTIOUS DISEASE DNA VACCINES
  • TABLE 32 INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF JULY 2009
  • TABLE 32 (CONTINUED)
• HSV
• HPV
• Influenza
• Influenza (Continued)
• Influenza (Continued)
• SARS
• Dengue
  • TABLE 33 DENGUE VACCINE LANDSCAPE, AS OF JULY 2009
• HBV
  • TABLE 34 HBV THERAPEUTIC LANDSCAPE, AS OF JULY 2009
• HBV (Continued)
• HCV
• Japanese Encephalitis
  • TABLE 35 JAPANESE ENCEPHALITIS VACCINE LANDSCAPE, AS OF JULY 2009
• CMV
  • TABLE 36 CMV VACCINE LANDSCAPE, AS OF JULY 2009
• HIV
  • TABLE 37 HIV DNA VACCINES CLINICAL TRIALS, AS OF JULY 2009
  • TABLE 37 (CONTINUED)
  • TABLE 37 (CONTINUED)
  • TABLE 37 (CONTINUED)
• HIV (Continued)
• BIODEFENSE DNA VACCINES
  • TABLE 38 BIODEFENSE DNA VACCINES CLINICAL TRIALS, AS OF JULY 2009
• ANIMAL HEALTH DNA VACCINES
  • TABLE 39 ANIMAL HEALTH DNA VACCINES CLINCAL PIPELINE, AS OF JULY 2009
  • TABLE 40 WEST NILE VIRUS HUMAN VACCINES LANDSCAPE, AS OF JULY 2009

Chapter-6: DNA VACCINE INDUSTRY

• VACCINE INDUSTRY STRUCTURAL SHIFTS
  • TABLE 41 VACCINE INDUSTRY STRUCTURAL SHIFTS
• INDUSTRY STRUCTURE
  • TABLE 42 VACCINE INDUSTRY STRUCTURE: TRADITIONAL VERSUS EMERGING
  • FIGURE 10 MARKETING OF APPROVED VACCINES IN THE UNITED STATES, 2009 (%)
  • TABLE 43 COMPARISON OF VACCINES AND PHARMACEUTICALS BUSINESSES
• INDUSTRY STRUCTURE (CONTINUED)
• DNA VACCINE INDUSTRY COMPETITORS
  • TABLE 44 DNA VACCINE INDUSTRY COMPETITOR POSITION
• DNA VACCINE COMMERCIAL VALUE CHAIN
  • FIGURE 11 DNA VACCINE COMMERCIAL VALUE CHAIN
• DNA VACCINE COMPETITOR STRATEGIC POSITIONING
  • TABLE 45 LARGE PHARMA VACCINE COMPANY STRATEGIC FOCUS
  • TABLE 46 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
  • TABLE 47 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC MARKET FOCUS
  • TABLE 47 (CONTINUED)
  • TABLE 48 SPECIALIZED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
• INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES
  • TABLE 49 INDUSTRY ACQUISITIONS AND MERGERS, 2006 - 2009
• INDUSTRY ACQUISITIONS AND ...... (CONTINUED)
  • TABLE 50 DNA VACCINE STRATEGIC ALLIANCES
• INDUSTRY ACQUISITIONS AND ...... (CONTINUED)

Chapter-7: DNA VACCINE MARKETS

• GROWTH DRIVING FORCES
  • TABLE 51 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
• MARKET FORECASTS
• OVERVIEW
  • TABLE 52 GLOBAL VALUE OF PHARMACEUTICAL MARKET BY TYPE, THROUGH 2014 ($ MILLIONS)
• Overview (Continued)
• DNA VACCINE MARKETS BY END USE
  • TABLE 53 GLOBAL VALUE OF DNA VACCINES BY END USE, THROUGH 2014 ($ MILLIONS)
• DNA VACCINE RESEARCH TOOLS MARKETS
  • TABLE 54 GLOBAL VALUE OF DNA VACCINES RESEARCH TOOLS MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
• DNA VACCINE CLINICAL MARKETS
  • TABLE 55 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
• Strategic Positioning
  • FIGURE 12 DNA VACCINE STRATEGIC MARKET GRID
• Allergies
  • TABLE 56 DNA VACCINE ALLERGY MARKET OPPORTUNITIES
• Cancer Therapeutics
  • TABLE 57 CAUSE OF DEATH, WORLDWIDE, 2004 AND 2030 (% OF ALL DEATHS)
• Infectious Diseases
• DNA CANCER VACCINES MARKET
  • TABLE 58 GLOBAL VALUE OF CANCER CLINICAL DNA VACCINES BY INDICATION, THROUGH 2014 ($ MILLIONS)
  • TABLE 59 DNA VACCINE CANCER MARKET OPPORTUNITIES
• DNA Cancer Vaccines Market (Continued)
• Melanoma
• Solid Tumors (Including Ovarian, Breast and Small-Cell Lung Cancer)
• Pancreatic Cancer
• INFECTIOUS DISEASE DNA VACCINE MARKETS
  • TABLE 60 GLOBAL VALUE OF INFECTIOUS DISEASE CLINICAL DNA VACCINES MARKET BY INDICATION, THROUGH 2014 ($ MILLIONS)
• CMV
• HBV
• HPV
• HCV
• HIV
• ANIMAL HEALTH DNA VACCINE MARKETS
  • TABLE 61 GLOBAL VALUE OF ANIMAL HEALTH CLINICAL DNA VACCINES MARKET, BY INDICATION, THROUGH 2014 ($ MILLIONS)
• Canine Melanoma
• Equine West Nile Virus
• Leishmaniasis
• Feline Leukemia Virus
• Fish Vaccine Adjuvants
• BIODEFENSE DNA VACCINE MARKETS
  • TABLE 62 GLOBAL VALUE OF BIODEFENSE CLINICAL DNA VACCINES MARKET, BY END USE, THROUGH 2014 ($ MILLIONS)
• Biodefense DNA Vaccine Markets (Continued)
• Biodefense DNA Vaccine Markets (Continued)
• DNA VACCINE MARKETS BY DELIVERY TECHNOLOGY
  • TABLE 63 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY DELIVERY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
• DNA VACCINE MARKET BY FORMAT AND FUNCTION
  • TABLE 64 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY VACCINE FORMAT, THROUGH 2014 ($ MILLIONS)
  • TABLE 65 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY FUNCTION, THROUGH 2014 ($ MILLIONS)
• DNA VACCINES MARKET BY GEOGRAPHY
  • TABLE 66 GLOBAL VALUE OF DNA VACCINES MARKET, BY GEOGRAPHICAL REGION, THROUGH 2014 ($ MILLIONS)

Chapter-8: PATENT STATUS

• INTRODUCTION
  • FIGURE 13 PATENT SCOPE FOR DNA VACCINES
• DNA VACCINE PATENTS BY COMPANY AND TECHNOLOGY SUBCLASS
  • FIGURE 14 U.S., EP, AND WO INTEGRATED BIOTECHNOLOGY COMPANY DNA VACCINE-RELATED PATENTS AND PATENT APPLICATIONS, AS OF JULY 2009
  • FIGURE 15 U.S., EP, AND WO INTEGRATED BIOTECHNOLOGY COMPANY DNA VACCINE-RELATED PATENTS BY TECHNOLOGY SUBCLASS AND PATENT APPLICATIONS, AS OF JULY 2009
• DNA VACCINE PATENTS BY COMPANY ...... (CONTINUED)
  • FIGURE 16 U.S., EP, AND WO INTEGRATED BIOTECHNOLOGY COMPANY DNA VACCINE-RELATED PATENTS BY TECHNOLOGY SUBCLASS, AS OF JULY 2009
• ANTIGENS AND ASSOCIATED PDNA
• ANTIGENS AND ASSOCIATED PDNA (CONTINUED)
  • TABLE 67 FUNDAMENTAL DNA INFLUENZA VACCINE PATENTS
• DNA VACCINE PATENTS BY GEOGRAPHY
  • FIGURE 17 GEOGRAPHICAL REGIONS IN WHICH PATENTS HAVE BEEN GRANTED AND PATENT APPLICATIONS FILEDFOR INTEGRATED BIOTECHNOLOGY COMPANIES, AS OF JULY 2009 (%)
• KEY INDUSTRY PATENTS ON OTHER PARTS OF THE VALUE CHAIN
  • TABLE 68 FUNDAMENTAL PATENTS ON DNA VACCINE DELIVERY, TARGETING, AND ADJUVANTS
• LITIGATION STATUS
  • TABLE 69 IP LITIGATION STATUS
• IP POSITION OF SELECTED DNA VACCINE COMPANIES
• GENEART
• GENEXINE
  • TABLE 70 GENEXINE PATENT FAMILIES
• IMMUNOMIC THERAPEUTICS, INC. (ITI)
• VICAL

Chapter-9: COMPANY PROFILES

• ADIMMUNE
• ALDEVRON, LLC
• ALTEA THERAPEUTICS
• ALTHEA TECHNOLOGIES, INC.
• ANGES MG, INC.
• AVAX TECHNOLOGIES
• BACILLIGEN, INC.
• BAVARIAN NORDIC A/S
• BAYHILL THERAPEUTICS
  • TABLE 71 BAYHILL DNA VACCINE PIPELINE
• BIGDNA, LTD.
• BIOJECT MEDICAL TECHNOLOGIES, INC.
• CHANGCHUN BAIKE PHARMACEUTICAL CO., LTD.
• COBRA BIOMANUFACTURING, PLC
• CRUCELL
• CYTOGENIX, INC.
  • TABLE 72 CYTOGENIX DNA VACCINE PRECLINICAL PIPELINE
• CYTO PULSE SCIENCES, INC.
  • TABLE 73 CYTO PULSE PIPELINE
• PROSTATE CANCER STUDY
• COLORECTAL CANCER STUDY
• TOLERANCE STUDIES
• HIV STUDY
• CYTRX CORP.
• DENDREON CORP.
• DYNAVAX TECHNOLOGIES
• THE EUROVACC FOUNDATION
• FIT BIOTECH OYJ, PLC
• GENEART AG
  • TABLE 74 GENEART STRATEGIC ALLIANCES
• GENEART AG (CONTINUED)
• GENETIC IMMUNITY
  • TABLE 75 GENETIC IMMUNITY DNA VACCINE PIPELINE
• GENEXINE
  • TABLE 76 GENEXINE DNA VACCINE PIPELINE
  • TABLE 77 GENEXINE PATENT FAMILIES
  • TABLE 77 (CONTINUED)
• IL-12 MUTANT
• EFFICIENT DNA AND RAD VECTORS
• SAFE ADENOVIRAL VECTOR
• GENOMIDEA, INC.
• GENOVAC GMBH
• GENOVAC GMBH (CONTINUED)
• GENVEC, INC.
• GEOVAX LABS
• GLAXOSMITHKLINE
• GLAXOSMITHKLINE (CONTINUED)
• GREENPAK BIOTECH, LTD.
• HENDERSON MORLEY, PLC
• ICHOR MEDICAL SYSTEMS, INC.
  • TABLE 78 ICHOR DNA VACCINE PIPELINE
• IMMUNOGENETIX THERAPEUTICS, INC.
• IMMUNOMIC THERAPEUTICS, INC.
  • TABLE 79 IMMUNOMIC DNA VACCINE PIPELINE
• JRC-LAMP-VAX
• SRW-LAMP-VAX
  • TABLE 80 ITI STRATEGIC ALLIANCES
• IMMUNOVACCINE TECHNOLOGIES, INC.
• IN CELL ART
• INDIAN IMMUNOLOGICALS
• INTERCELL AG
• INVIVOGEN
• JUVARIS BIOTHERAPEUTICS, INC.
  • TABLE 81 JUVARIS DNA VACCINE PIPELINE
• LENTIGEN CORP.
• LIPOXEN, PLC
• MANNKIND CORP.
• MANNKIND CORP. (CONTINUED)
• MEDICAL MARKETING INTERNATIONAL GROUP, PLC
  • TABLE 82 GENVAX PIPELINE
• MERCK
  • TABLE 83 MERCK DNA VACCINE PIPELINE
• MERIAL
• MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
• MOLOGEN AG
• MULTIMERIC BIOTHERAPEUTICS, INC.
• NATURE TECHNOLOGY CORP.
• NIH VACCINE RESEARCH CENTER
• NOVARTIS
• OXFORD BIOMEDICA, PLC
• PFIZER
• PHYTOVATION BV
• PLASMIDFACTORY GMBH & CO.
• PROFECTUS BIOSCIENCES, INC.
• QED BIOSCIENCE, INC.
• SANOFI-AVENTIS
• STATENS SERUM INSTITUT
• SUPRATEK PHARMA
• TRIPEP
  • TABLE 84 TRIPEP THERAPEUTIC DNA VACCINE PIPELINE
• VAXGEN, INC.
• VAXXION THERAPEUTICS, INC.
• VAXONCO, INC.
• VECTURA GROUP, PLC
• VGX PHARMACEUTICALS, INC.
• VGX PHARMACEUTICALS, INC. (CONTINUED)
  • TABLE 85 INOVIO AND VGX DNA VACCINE CLINICAL TRIALS, AS OF JULY 2009
• VGX PHARMACEUTICALS, INC. (CONTINUED)
• VGXI, INC.
• VICAL, INC.
  • TABLE 86 VICAL STRATEGIC ALLIANCES
  • TABLE 87 VICAL DNA VACCINE PIPELINE
  • TABLE 87 (CONTINUED)
  • FIGURE 18 VICAL LINEAR DNA VACCINE STRATEGIC POSITIONING
• VIROMED CO., LTD.
• VIROMED CO., LTD. (CONTINUED)

相關商品

矚目市場調查報告書

全套市場調查報告定期訂閱

Market Research Report Subscription

疫苗相關市場調查報告書

大腸癌、血管增生、癌症疫苗分析
Triple Analysis: Colorectal Cancer, Angiogenesis and Cancer Vaccines
價格 : US $ 5175
出版日期 : 2012年01月

白血病、血管增生、癌症疫苗：藥劑開發策略分析
Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines
價格 : US $ 5175
出版日期 : 2012年01月

淋巴癌、血管增生、癌症疫苗：藥劑開發策略分析
Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines
價格 : US $ 5175
出版日期 : 2012年01月

BCC Research發行的製藥相關市場調查報告書

全球的肝臟疾病治療藥市場

Liver Disease Treatments: The Global Market

價格 : US $ 4850

出版日期 : 2012年01月

2011年醫療市場調査評論

2011 Healthcare Research Review

價格 : US $ 850

出版日期 : 2012年01月

肺部給藥系統:技術和全球市場

Pulmonary Drug Delivery Systems: Technologies and Global Markets

價格 : US $ 4850

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!